Mannitolo S.A.L.F.

Mannitol, the active ingredient in Mannitolo S.A.L.F., is a osmotic diuretic presented as a solution for injection for intravenous use. It is employed to reduce intracranial pressure, promote diuresis in acute renal failure, and facilitate renal excretion of toxins in hospitalized patients who require rapid fluid shifts.

GNH USA supplies Mannitolo S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mannitol is an osmotic diuretic used in clinical situations that require rapid reduction of fluid volume or pressure.

- Reduction of intracranial pressure: lowers cerebral edema and intracranial pressure in patients with head injury or neurosurgical conditions. - Acute renal failure: promotes diuresis to assist renal clearance in patients with oliguria. - Renal excretion of toxins: facilitates urinary elimination of certain nephrotoxic substances.

Mannitol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often reported during infusion. - Nausea and vomiting: gastrointestinal upset related to rapid osmotic shifts. - Thirst or dry mouth: sensation of increased fluid loss. - Electrolyte imbalance: mild hyponatremia or hypokalemia. - Dizziness: transient light‑headedness during or after administration. - Transient hypotension: due to rapid intravascular volume expansion.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in the lungs, especially in patients with cardiac dysfunction. - Severe hypernatremia: markedly elevated serum sodium requiring urgent correction. - Anaphylactoid reaction: rare hypersensitivity with rash, bronchospasm, or shock. - Worsening renal failure: excessive diuresis leading to further kidney injury. - Seizures: secondary to electrolyte disturbances. - Cardiac arrhythmia: irregular heart rhythm linked to electrolyte shifts.

Mannitol should be administered with careful clinical monitoring to minimize risks.

- Renal function: assess baseline renal status and monitor urine output. - Intracranial pressure: continuously evaluate neurologic status and imaging when indicated. - Electrolytes and osmolality: check serum electrolytes and osmolality before and during therapy. - Cardiovascular status: avoid rapid infusion in patients with heart failure or compromised circulation. - Volume status: ensure adequate intravascular volume to prevent hypotension. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several medications, influencing fluid and electrolyte balance.

Major Interactions (Avoid): - Loop diuretics: may cause excessive diuresis and profound electrolyte loss. - Insulin: can potentiate hypoglycemia due to rapid fluid shifts. - Lithium: increased risk of lithium toxicity from altered renal clearance.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance renal effects and require monitoring of kidney function. - NSAIDs: can reduce the diuretic response and affect renal perfusion.